Andrew Phillips

Andrew Phillips

Company: AbbVie

Job title: Director, Next Generation Antibody Drug Conjugates

Bio:

Dr Phillips earned his Ph.D. from the University of Glasgow, performed postdoctoral studies and the NCI and was an Assistant Professor at the Medical College of Georgia prior to joining Abbott/Abbvie. At Abbvie Dr Phillips has been involved in multiple ADC programs including a number that have entered clinical development. These include depatuximab mafadotin, Abbvie’s first ADC, where he served as the lead biologist and ABBV-155, Abbvie’s first in-class BCL-XL inhibitor ADC for which he served as Project Director. Dr Phillips current role is as Director, Next Generation Antibody Drug Conjugates.

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.